The use of GM1 ganglioside for Parkinson’s Disease treatmentL a systematic review

Read full text Summarise with VIRAT
Authors: Marcella Ferreira Gobbi, Simone da Silva Cunha, LUCIANA MUNHOZ, Disnaldo Avelar Souza Rodrigues
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This project aims to systematically review the available scientific evidence on the use of GM1 ganglioside as a potential therapeutic strategy for Parkinson’s disease (PD). Parkinson’s disease is neurodegenerative disorder that rank second most common after Alzheimer’s disease, affecting approximately 1% of the population aged over 60 years. PD is characterized by selective and progressive dopaminergic (DA) neurodegeneration in the substantia nigra (SN) and associated with Lewy body (LB) formation in surviving DA neurons. The cause of PD is multifactorial, and involves genetic and environmental factors. The treatment for PD does not offer a definitive cure, but focuses on controlling symptoms and maintaining quality of life. The treatment can happen with drug, surgical, supportive, lifestyle treatment and new perspectives, like gene therapy. The Therapeutic strategies aimed at elevating GM1 levels are extremely attractive in PD contexto, because the GM1 has the capability to modulate the neurotrophins’ signalings and to avoid αS aggregation clearly highlights its role as regulator of neuronal homeostasis, capable of preventing the neurodegeneration. The GM1 ganglioside is a glycosphingolipid abundantly present in neuronal membranes, where it plays important roles in membrane organization, signal transduction, neuronal survival, and synaptic function. The purpose of this systematic review is to identify, analyze, and synthesize the existing evidence on the effects of GM1 in experimental models of Parkinson’s disease, including in vitro cellular systems and in vivo animal models. The review will focus on studies evaluating molecular, cellular, neuropathological, and functional outcomes associated with GM1 administration. Electronic searches will be conducted in biomedical databases such as PubMed using predefined search strategies combining terms related to GM1 ganglioside and Parkinson’s disease. Acceptable studies will include original experimental investigations evaluating GM1 as an intervention in models of PD. Studies not involving PD models or not evaluating GM1 as a therapeutic intervention will be excluded. Data extraction will include experimental model characteristics, intervention details, outcome measures, and key findings. The expected outcome of this review is to provide a synthesis of the current experimental evidence supporting the potential therapeutic role of GM1 in Parkinson’s disease. By consolidating findings from the existing literature, this review aims to clarify the biological rationale for GM1-based interventions, identify knowledge gaps, and inform the design of future translational and clinical studies evaluating GM1 in patients with PD.

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Lysosomal Storage Disorders Research Alzheimer's disease research and treatments

Publication details

Publication date
1 January 2026
Language
EN
Document type
Preprint